Key Takeaways
- In the ISCHEMIA-EXTEND follow-up, 11-year death rates were 25.8% with an initial invasive strategy and 26.9% with pills alone — no significant difference.
- Fewer cardiovascular deaths in the invasive group were roughly offset by more non-cardiovascular deaths.
- The original trial found better angina relief with the invasive approach, so the choice turns on symptoms, not survival.
What If Opening a Blocked Artery Doesn't Help You Live Longer?
Imagine being diagnosed with serious heart disease. One option is to undergo an invasive procedure. The other is to start with medication.
Which approach gives you more years of life?
Researchers have now followed thousands of patients for 11 years to find out. The surprising answer: neither approach came out ahead on overall survival.
The 11-Year Survival Test
The ISCHEMIA-EXTEND study followed 5,179 people with chronic coronary disease and moderate or severe ischemia at 320 sites in 37 countries.
After 11 years, 25.8% of the group assigned to an initial invasive strategy had died, compared with 26.9% of the group managed with medication first.
The adjusted hazard ratio was 0.97 (95% CI, 0.86–1.09), a difference well within chance.
In practical terms, estimated survival differed by about 14 days over 11 years.
Why Did the Two Approaches End Up So Close?
The numbers reveal an interesting twist.
Cardiovascular deaths were somewhat lower in the invasive group: 15.8% versus 17.1%.
But non-cardiovascular deaths were somewhat higher: 9.1% versus 8.1%.
The two differences roughly cancelled each other out.
Researchers calculate only an 18% probability that the invasive strategy improves survival by more than one percentage point.
In other words, the long-term survival advantage remains unproven.
Does That Mean Stents and Surgery Are Pointless?
Not at all.
In the original ISCHEMIA trial, patients who arrived with angina experienced greater symptom relief from the invasive approach.
That distinction matters. A procedure may help someone feel better without necessarily helping them live longer.
There are also important limits to these findings. The results do not apply to people with left main disease, very weak heart function or a recent heart attack — groups excluded from the trial.
And "invasive" included bypass surgery, not stents alone.
Health note: This is general information about a research study, not medical advice. Decisions about heart procedures depend on your symptoms, anatomy and overall health — talk to your cardiologist about what fits your situation.
The Twikup Take
Eleven years and more than a thousand deaths later, the survival scoreboard reads even.
For stable heart disease, the honest conversation is no longer "will this save my life?" — it is "will this ease my symptoms?"
Image: AI-generated illustration.